Amedeo Smart

Free Medical Literature Service



Ischemic Heart Disease

  Free Subscription

Articles published in
    April 2023
  1. GAUDINO M, Andreotti F, Kimura T
    Current concepts in coronary artery revascularisation.
    Lancet. 2023 Apr 27:S0140-6736(23)00459-2. doi: 10.1016/S0140-6736(23)00459.
    >> Share

    March 2023
  2. DILETTI R, den Dekker WK, Bennett J, Schotborgh CE, et al
    Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial.
    Lancet. 2023 Mar 3:S0140-6736(23)00351-3. doi: 10.1016/S0140-6736(23)00351.
    >> Share

  3. RIDKER PM, Bhatt DL, Pradhan AD, Glynn RJ, et al
    Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.
    Lancet. 2023 Mar 3:S0140-6736(23)00215-5. doi: 10.1016/S0140-6736(23)00215.
    >> Share

  4. TARDIF JC, Samuel M
    Inflammation contributes to cardiovascular risk in patients receiving statin therapy.
    Lancet. 2023 Mar 3:S0140-6736(23)00454-3. doi: 10.1016/S0140-6736(23)00454.
    >> Share

  5. PUSTJENS TFS, Vriesendorp PA, Van't Hof AWJ
    Revascularisation in acute coronary syndromes: change in practice?
    Lancet. 2023 Mar 3:S0140-6736(23)00403-8. doi: 10.1016/S0140-6736(23)00403.
    >> Share

  6. HE J, Ouyang N, Guo X, Sun G, et al
    Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.
    Lancet. 2023 Mar 2:S0140-6736(22)02603-4. doi: 10.1016/S0140-6736(22)02603.
    >> Share

  7. YAN LL, Karmacharya BM
    Improving cardiovascular health in rural China and beyond.
    Lancet. 2023 Mar 2:S0140-6736(23)00092-2. doi: 10.1016/S0140-6736(23)00092.
    >> Share

    February 2023
  8. WANG Y, Li S, Pan Y, Li H, et al
    Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.
    Lancet. 2023 Feb 8:S0140-6736(22)02600-9. doi: 10.1016/S0140-6736(22)02600.
    >> Share

  9. MENON BK, Singh N, Sylaja PN
    Tenecteplase use in patients with acute ischaemic stroke.
    Lancet. 2023 Feb 8:S0140-6736(22)02633-2. doi: 10.1016/S0140-6736(22)02633.
    >> Share

    January 2023
  10. TAWFIQ E, Selak V, Elwood JM, Pylypchuk R, et al
    Performance of cardiovascular disease risk prediction equations in more than 14 000 survivors of cancer in New Zealand primary care: a validation study.
    Lancet. 2023 Jan 23:S0140-6736(22)02405-9. doi: 10.1016/S0140-6736(22)02405.
    >> Share

    Cardiovascular risk assessment in survivors of cancer.
    Lancet. 2023 Jan 23:S0140-6736(22)02582-X. doi: 10.1016/S0140-6736(22)02582.
    >> Share

  12. WENZL FA, Luscher TF
    Application of a sex-specific GRACE score in practice - Authors' reply.
    Lancet. 2023;401:23.
    >> Share

  13. KIMENAI DM, Mills NL
    Application of a sex-specific GRACE score in practice.
    Lancet. 2023;401:22-23.
    >> Share

  14. CONRAD N, McMurray JJV
    Cardiovascular risk in systemic autoimmune diseases - Authors' reply.
    Lancet. 2023;401:22.
    >> Share

  15. FUNADA S, Luo Y, Nishioka N, Yoshioka T, et al
    Cardiovascular risk in systemic autoimmune diseases.
    Lancet. 2023;401:21.
    >> Share

  16. CAFARO G, Perricone C, Gerli R, Bartoloni E, et al
    Cardiovascular risk in systemic autoimmune diseases.
    Lancet. 2023;401:21-22.
    >> Share

    December 2022
  17. BATRA P, Khera AV
    Machine learning to assess coronary artery disease status-is it helpful?
    Lancet. 2022 Dec 20:S0140-6736(22)02584-3. doi: 10.1016/S0140-6736(22)02584.
    >> Share

  18. FORREST IS, Petrazzini BO, Duffy A, Park JK, et al
    Machine learning-based marker for coronary artery disease: derivation and validation in two longitudinal cohorts.
    Lancet. 2022 Dec 20:S0140-6736(22)02079-7. doi: 10.1016/S0140-6736(22)02079.
    >> Share

    November 2022
  19. COUGHLAN JJ, Kastrati A
    Bivalirudin in patients with ST-segment elevation myocardial infarction.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02162.
    >> Share

  20. LI Y, Liang Z, Qin L, Wang M, et al
    Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)01999.
    >> Share

    October 2022
  21. MACKENZIE IS, Rogers A, Poulter NR, Williams B, et al
    Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial.
    Lancet. 2022 Oct 11. pii: S0140-6736(22)01786.
    >> Share

  22. MACKENZIE IS, Hawkey CJ, Ford I, Greenlaw N, et al
    Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
    Lancet. 2022;400:1195-1205.
    >> Share

  23. NI AINLE F, Middeldorp S, Le Gal G, Hunt BJ, et al
    Protecting patients during a shortage of thrombolytic agents.
    Lancet. 2022;400:1193-1194.
    >> Share

  24. TANAKA A, Node K
    Xanthine oxidase inhibition for cardiovascular disease prevention.
    Lancet. 2022;400:1172-1173.
    >> Share

    September 2022
  25. WALLI-ATTAEI M, Rosengren A, Rangarajan S, Breet Y, et al
    Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study.
    Lancet. 2022;400:811-821.
    >> Share

  26. MANFRINI O, Bugiardini R
    Behavioural risk factors and cardiovascular disease: are women at higher risk?
    Lancet. 2022;400:788-789.
    >> Share

    August 2022
  27. WENZL FA, Kraler S, Ambler G, Weston C, et al
    Sex-specific evaluation and redevelopment of the GRACE score in non-ST-segment elevation acute coronary syndromes in populations from the UK and Switzerland: a multinational analysis with external cohort validation.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01483.
    >> Share

    Risk stratification and health inequalities in women with acute coronary syndrome: time to move on.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01607.
    >> Share

  29. CONRAD N, Verbeke G, Molenberghs G, Goetschalckx L, et al
    Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01349.
    >> Share

    July 2022
  30. KIM BK, Hong SJ, Lee YJ, Hong SJ, et al
    Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.
    Lancet. 2022 Jul 18. pii: S0140-6736(22)00916.
    >> Share

    June 2022
  31. SANDSET EC, Tsvigoulis G
    Tenecteplase for acute ischaemic stroke.
    Lancet. 2022 Jun 28. pii: S0140-6736(22)01107.
    >> Share

  32. MENON BK, Buck BH, Singh N, Deschaintre Y, et al
    Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
    Lancet. 2022 Jun 28. pii: S0140-6736(22)01054.
    >> Share

    May 2022
  33. DELGADO-LISTA J, Alcala-Diaz JF, Torres-Pena JD, Quintana-Navarro GM, et al
    Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial.
    Lancet. 2022 May 4. pii: S0140-6736(22)00122.
    >> Share

    April 2022
  34. BERGMARK BA, Mathenge N, Merlini PA, Lawrence-Wright MB, et al
    Acute coronary syndromes.
    Lancet. 2022;399:1347-1358.
    >> Share

    February 2022
  35. BODEN WE, Kaski JC, Al-Lamee R, Weintraub WS, et al
    What constitutes an appropriate empirical trial of antianginal therapy in patients with stable angina before referral for revascularisation?
    Lancet. 2022;399:691-694.
    >> Share

    November 2021
  36. CALDEIRA D, Pinto FJ
    COVID-19 and myocardial infarction.
    Lancet. 2021;398:1963-1964.
    >> Share

  37. KATSOULARIS I, Fonseca-Rodriguez O, Farrington P, Lindmark K, et al
    COVID-19 and myocardial infarction - Authors' reply.
    Lancet. 2021;398:1964.
    >> Share

  38. SABATINE MS, Bergmark BA, Murphy SA, O'Gara PT, et al
    Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis.
    Lancet. 2021 Nov 12. pii: S0140-6736(21)02334.
    >> Share

  39. MEHRAN R, Owen R, Chiarito M, Baber U, et al
    A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry.
    Lancet. 2021 Nov 12. pii: S0140-6736(21)02326.
    >> Share

  40. BELLEY-COTE EP, Devereaux PJ
    PCI versus CABG for left main coronary artery disease: is the jury still out?
    Lancet. 2021 Nov 12. pii: S0140-6736(21)02491.
    >> Share

  41. KANG J, Koo BK, Park KW, Shin ES, et al
    Aspirin versus clopidogrel after percutaneous coronary intervention - Authors' reply.
    Lancet. 2021;398:1685-1686.
    >> Share

  42. PAREEK M, Byrne C
    Aspirin versus clopidogrel after percutaneous coronary intervention.
    Lancet. 2021;398:1685.
    >> Share

  43. BYRNE RA, McGovern L
    Angiography-derived quantitative flow ratio guidance of coronary intervention: measure twice, cut once.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02397.
    >> Share

  44. XU B, Tu S, Song L, Jin Z, et al
    Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02248.
    >> Share

    October 2021
  45. DEL PRATO S, Kahn SE, Pavo I, Weerakkody GJ, et al
    Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
    Lancet. 2021 Oct 18. pii: S0140-6736(21)02188.
    >> Share

  46. KIM CJ, Park MW, Kim MC, Choo EH, et al
    Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised tr
    Lancet. 2021;398:1305-1316.
    >> Share

  47. TSAMPASIAN V, Maart C, Vassiliou VS, Garg P, et al
    Mitral valve disease in sarcoidosis diagnosed by cardiovascular magnetic resonance.
    Lancet. 2021;398:1358.
    >> Share

    September 2021
  48. PINTO FJ, Pineiro D, Banerjee A, Perel P, et al
    World Heart Day 2021: COVID-19, digital health, and tackling cardiovascular disease.
    Lancet. 2021 Sep 28. pii: S0140-6736(21)02144.
    >> Share

  49. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).
    Lancet. 2021 Sep 7. pii: S0140-6736(21)01122.
    >> Share

    March 2021
    The risk of no risk in STEMI.
    Lancet. 2021;397:1039-1040.
    >> Share

  51. FIGTREE GA, Vernon ST, Hadziosmanovic N, Sundstrom J, et al
    Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
    Lancet. 2021;397:1085-1094.
    >> Share

    February 2021
  52. TAKAHASHI K, van Klaveren D, Steyerberg EW, Onuma Y, et al
    Concerns with the new SYNTAX score - Authors' reply.
    Lancet. 2021;397:795-796.
    >> Share

  53. FREEMANTLE N, Pagano D
    Concerns with the new SYNTAX score.
    Lancet. 2021;397:795.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016